Similarly, CDC7 (essential for the G1/S transition and initiation of DNA replication) and MAP3K8 (which activates MAPK and JNK) have not been validated as therapeutic targets in ccRCC and warrant further study. This evidence concerns the gene MAP3K8 and nonpapillary renal cell carcinoma.